CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
LY2216684 +2 moredrug
Likely dose
Ortho Cyclen 35 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01373931
NCT01373931Phase 1Completed
CompareCT.gov

Effect of LY2216684 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Eli Lilly and Company·interventional·Posted Jun 15, 2011·Updated Oct 23, 2018

In Brief

A Phase 1 clinical trial evaluating LY2216684, Ortho Cyclen, and 1 other intervention for Depressive Disorder, Major. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®. This study will run approximately 93 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.0 years ago

Interventions

LY2216684drug

Administered orally

Ortho Cyclendrug

35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally

Placebodrug

Administered orally